证券代码：688321 证券简称：微芯生物 公告编号：2023-057 临床阶段：I 期临床试验 深圳微芯生物科技股份有限公司 自愿披露关于 CS32582 胶囊临床试验申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）全资子公司成都微芯 药业有限公司近日收到国家药品监督管理局（以下简称"国家药监局"）签发的境 内生产药品注册临床试验的《受理通知书》，CS32582 胶囊的临床试验申请获得 受理。 本次申请为新药临床试验申请，在临床试验申请获得受理后，自受理之日起 60 日内未收到药审中心的否定或质疑意见的，公司便可以按照提交的方案开展 临床试验。临床试验能否最终开展存在不确定性，敬请广大投资者注意防范投资 风险，谨慎决策。现将相关情况公告如下： 一、药品基本情况 1、产品名称：CS32582 胶囊 受理号：CXHL2300877（3 mg）、CXHL2300878（12 mg） 适应症：银屑病 申请事项：境内生产药品注册临床试验 申请人：成 ...

证券代码：688321 证券简称：微芯生物 公告编号：2023-058 深圳微芯生物科技股份有限公司 1、被冻结股份的基本情况 被冻结人：天府清源控股有限公司 冻结申请人：中原信托有限公司 冻结机关：湖北省宜昌市中级人民法院 冻结期限：2023 年 8 月 1 日至 2026 年 7 月 31 日 深圳微芯生物科技股份有限公司（以下简称"公司"）股东天府清源控股有限 公司（以下简称"天府清控"）持有公司 8,214,410 股，占公司总股本的比例 为 2%。本次冻结数量为 8,214,410 股，占公司总股本的比例为 2%。 天府清控系股东博奥生物集团有限公司的一致行动人，博奥生物集团有限公 司持有公司的股份数量为 34,705,162 股，占公司总股本的比例为 8.44%，两 者合计持有公司的股份比例为 10.44%。 天府清控不属于公司的控股股东、实际控制人，其股份被司法冻结事项不影 响公司的控制权稳定，亦不会对公司的日常经营管理造成影响。 关于持股 5%以上股东部分股份被司法冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of 500 million RMB, representing a 25% year-over-year growth[1]. - The company achieved operating revenue of CNY 241.60 million in the first half of 2023, representing an 11.89% increase compared to the same period last year[21]. - The company reported a net profit attributable to shareholders of CNY 155.69 million, a significant increase compared to a net loss of CNY 19.29 million in the same period last year[26]. - Future guidance includes an expected EBITDA margin of 25% for the full year 2023, reflecting strong operational performance[1]. - Operating revenue increased by 11.89% year-on-year, driven by steady growth in sales of two major commercialized products: sales of Sidabone tablets rose by 17.40%, and sales of Siglitazone sodium tablets increased by 28.38%[114]. Research and Development - Research and development efforts have led to the introduction of two new innovative drugs, with expected market approval by Q4 2023[1]. - The company has allocated 100 million RMB for R&D in the upcoming fiscal year, focusing on advanced therapeutic technologies[1]. - Research and development expenses amounted to CNY 65.36 million, with a significant portion allocated to the dual antibody project, NWY001, totaling CNY 50 million[25]. - The company has a robust R&D pipeline with multiple candidates at various stages, including CS1008, CS1010, and CS1011 in early discovery and preclinical phases[40]. - Total R&D investment reached approximately ¥247.59 million, a significant increase of 89.46% compared to ¥130.68 million in the same period last year[73]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 30% based on new product launches and market expansion strategies[1]. - The company is planning to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years[1]. - A strategic acquisition of a biotech firm is in progress, which is expected to enhance the company's product pipeline and increase overall market competitiveness[1]. - The company is focusing on enhancing its R&D capabilities in response to national policies encouraging new drug development and expediting approval processes[37]. Product Development and Approval - The company has initiated the process validation for the second production line of Siglitazone, expected to complete in Q3 2023[21]. - The company has received acceptance for new indications for Sidabone and Siglitazone, which will further expand their sales[22]. - The company has submitted a new drug application for Sidabone targeting diffuse large B-cell lymphoma, which has been prioritized for review by the CDE[83]. - The company has received clinical trial approval for the CS23546 tablet for late-stage malignant tumor patients, with the approval number 2023LP01181[69]. Financial Management and Investments - The company recognized an investment income of 248,879,500 RMB from the loss of control over Microchip New Domain, which significantly boosted net profit for the period[115]. - The company’s total assets included 170,271,955.93 RMB in trading financial assets, a decrease of 41.50% from the previous year, mainly due to the redemption of maturing structured deposits[118]. - The company has a cash management strategy in place for idle funds, focusing on high-security and high-liquidity investment products[185]. - The company has ongoing rental agreements with Microchip Biology for properties, with total rental income of CNY 1,362,712.00[175]. Environmental Responsibility - The company has established a comprehensive environmental monitoring plan, including monthly monitoring of VOCs and hydrogen chloride at various emission points[144]. - The company’s pollution control facilities at both Shenzhen and Chengdu production bases are operating normally without any exceedance of emission standards[142]. - The company reported specific pollutant emissions: COD at 0.11722 tons, ammonia nitrogen at 0.001862 tons, total phosphorus at 0.001489 tons, nitrogen oxides at 0.4712 tons, and VOCs at 0.129096 tons[140]. - The company has committed to long-term holding of its shares and will comply with regulations regarding share reduction after the lock-up period[148]. Corporate Governance and Compliance - The controlling shareholder, XIANPING LU, has committed not to interfere with the company's management or harm its interests[154]. - The company has made a commitment to ensure that the prospectus submitted for the IPO does not contain false statements or omissions, and will bear legal responsibility for its accuracy[155]. - The company has established a linkage between the compensation measures and the remuneration system to ensure alignment with shareholder interests[165]. - There are no significant lawsuits or arbitration matters reported during the reporting period, indicating a stable legal standing for the company[170].

（一）实际募集资金情况 1. 2019 年首次公开发行股票 根据中国证券监督管理委员会 2019 年 7 月 17 日出具的《关于同意深圳微 芯生物科技股份有限公司首次公开发行股票注册的批复》（证监许可[2019]1299 号），公司首次公开发行人民币普通股（A 股）50,000,000 股，每股面值人民币 1.00 元，每股发行价人民币 20.43 元，募集资金总额为人民币 1,021,500,000.00 元，扣除与募集资金相关的发行费用共计人民币 76,311,750.00 元（不含增值税） 后，实际募集资金净额为人民币 945,188,250.00 元。上述募集资金于 2019 年 8 月 6 日到账，毕马威华振会计师事务所（特殊普通合伙）对公司首次公开发行股 票的资金到位情况进行了审验，并出具了毕马威华振验字第 1900341 号《验资报 告》。 2. 2022 年向不特定对象发行可转换公司债券 根据中国证监会《关于同意深圳微芯生物科技股份有限公司向不特定对象发 行可转换公司债券注册的批复》（证监许可〔2022〕1234 号），公司向不特定对象 发行 500 万张可转换公司债券（以下简称"可转债"） ...

证券代码：688321 证券简称：微芯生物 公告编号：2023-056 深圳微芯生物科技股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 08 月 18 日(星期五) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 12 日(星期六) 至 08 月 17 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@chipscreen.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 深圳微芯生物科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 12 日发布公司 2023 年半年度报告，为便于广大投资者更全面 深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 08 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥106,525,525.73, representing a year-on-year increase of 1.96%[5] - The net profit attributable to shareholders was -¥32,476,835.40, with a net profit excluding non-recurring gains and losses at -¥38,248,035.55, both figures indicating a significant loss[5] - Total revenue for Q1 2023 was CNY 106,525,525.73, an increase from CNY 104,479,337.72 in Q1 2022, representing a growth of approximately 1.96%[19] - The net loss for Q1 2023 was CNY 35,783,904.58, compared to a net loss of CNY 3,731,829.11 in Q1 2022, reflecting a significant decline in profitability[20] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0798, compared to CNY -0.0092 in Q1 2022, indicating a worsening in earnings performance[21] Research and Development - The total R&D investment amounted to ¥85,986,806.51, which is an increase of 32.28% compared to the previous period, accounting for 80.72% of operating revenue, up by 18.50 percentage points[6] - Research and development expenses rose to CNY 52,986,316.31 in Q1 2023, compared to CNY 36,500,212.56 in Q1 2022, marking an increase of approximately 45.4%[20] - The company is focused on enhancing its research and development capabilities to drive future growth and innovation[14] - The company continues to invest heavily in R&D, which may indicate a focus on future product development and market expansion despite current financial challenges[20] Cash Flow and Assets - The cash flow from operating activities showed a net outflow of -¥48,582,917.14, reflecting a decrease of 512.03% due to increased R&D expenditures and tax payments[6] - In Q1 2023, the net cash flow from operating activities was -48,582,917.14, a significant decline compared to 11,791,112.97 in Q1 2022[24] - Total assets at the end of the reporting period were ¥3,009,324,516.46, a 3.92% increase from the end of the previous year[6] - The total assets increased to CNY 3,009,324,516.46 in Q1 2023, up from CNY 2,895,799,412.95 in Q1 2022, showing a growth of about 3.9%[17] - The total current assets of RMB 1,253,859,413.43 as of March 31, 2023, an increase from RMB 1,184,135,081.82 as of December 31, 2022, reflecting a growth of approximately 5.7%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,866[11] - The company's equity attributable to shareholders decreased by 4.03% to ¥1,454,331,002.16 compared to the end of the previous year[6] - The company has a significant shareholder structure, with the top shareholder, 博奥生物集团有限公司, holding 34,705,162 shares, which is 8.44% of the total shares[12] - The second-largest shareholder, 深圳市海粤门生物科技开发有限公司, holds 22,936,008 shares, accounting for 5.58%[12] - The company has a total of 10 major shareholders, with the cumulative shareholding of the top 10 reaching approximately 56.5%[12] Operating Costs and Liabilities - Total operating costs for Q1 2023 were CNY 144,662,416.93, up from CNY 111,098,530.22 in Q1 2022, indicating an increase of about 30.2%[19] - Total liabilities reached CNY 1,433,830,911.03 in Q1 2023, compared to CNY 1,320,098,552.55 in Q1 2022, indicating an increase of approximately 8.6%[17] Market and Product Development - The sales volume of Seglitazone increased by 218% year-on-year after the implementation of the medical insurance price on March 1, 2023, although revenue decreased due to significant price cuts[6] - The company is actively involved in market expansion and new product development, although specific details were not disclosed in the report[14]

Financial Performance - In 2022, the company achieved a net profit attributable to shareholders of 17.48 million yuan, with the parent company reporting a net profit of 83.56 million yuan[9]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[17]. - The company's operating revenue for 2022 was CNY 529.94 million, representing a 23.11% increase compared to CNY 430.45 million in 2021[26]. - The net profit attributable to shareholders decreased by 20.37% to CNY 17.48 million in 2022 from CNY 21.96 million in 2021[26]. - The net profit after deducting non-recurring gains and losses increased by 267.00% to CNY 6.52 million in 2022, compared to a loss of CNY 3.91 million in 2021[26]. - The cash flow from operating activities for 2022 was CNY 43.30 million, a decrease of 65.30% from CNY 124.78 million in 2021[26]. - The company's total assets at the end of 2022 were CNY 2.90 billion, a 52.86% increase from CNY 1.89 billion at the end of 2021[26]. - The basic earnings per share for 2022 were CNY 0.0430, down 19.93% from CNY 0.0537 in 2021[27]. - The company reported a net asset attributable to shareholders of CNY 1.52 billion at the end of 2022, a 6.90% increase from CNY 1.42 billion at the end of 2021[26]. Research and Development - The company has established a relatively complete R&D system and a cost-controlled production and quality system, supporting sustainable growth[3]. - The company plans to focus on "cost reduction and efficiency enhancement" in 2023, aiming for clinical development aimed at public listing and exploring innovative treatment methods beyond small molecules[5]. - Research and development expenses increased by 20%, totaling 200 million RMB, focusing on new drug formulations and technologies[19]. - The R&D expenditure accounted for 54.33% of operating revenue in 2022, slightly down from 54.44% in 2021[28]. - The company is conducting four original drug clinical trials covering 17 indications globally[38]. - The company has a comprehensive and experienced clinical development team that manages key clinical trial operations internally, with some early-stage exploratory trials conducted in collaboration with CROs[59]. - The company has established a unique chemical genomics technology platform for drug discovery, enhancing the efficiency and reducing risks in clinical development[87]. - The company is actively pursuing multiple innovative drug candidates and clinical trials, with significant investments in market expansion and R&D[98]. Product Development and Market Expansion - The company successfully completed patient enrollment for two key Phase III clinical trials: the combination of Sidabamine with R-CHOP for diffuse large B-cell lymphoma and the combination of Siglitazone with Metformin for type 2 diabetes[4]. - Siglitazone was successfully included in the national medical insurance directory, enhancing its market accessibility[4]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[18]. - New product launches included two innovative drugs, which are expected to contribute approximately 300 million RMB in revenue in 2023[17]. - The company is actively seeking international partners to promote collaborative development of international clinical trials[5]. - The company has made significant progress in the construction of its pilot workshop for anti-tumor oral formulations, which is now operational[49]. - The company is actively negotiating for the inclusion of Sidabenos for breast cancer indications in the medical insurance directory and working on the inclusion of Siglitazone in the essential drug list[169]. Strategic Initiatives - The company decided not to distribute cash dividends or issue bonus shares for the 2022 fiscal year, prioritizing sustainable development and funding needs[9]. - The company completed a strategic acquisition of a biotech firm for 500 million RMB, enhancing its product pipeline[17]. - The company plans to invest 100 million RMB in digital transformation initiatives to enhance operational efficiency[19]. - A new partnership with a leading pharmaceutical company was established to co-develop therapies, expected to generate 150 million RMB in joint revenue[17]. - The company is committed to enhancing compliance and transparency while striving for high-speed, sustainable, and high-quality growth[4]. Challenges and Risks - The company has faced unprecedented challenges in 2022 but continues to develop and adapt to the changing environment[3]. - The company faces risks related to the long and costly nature of drug development, which may impact its financial performance if projects do not meet regulatory approval or market expectations[99]. - The competition in the Me-too and Me-better drug development space is intensifying, leading to increased risks for projects in this category[70]. - The company faces risks related to increased competition from newly approved drugs targeting the same indications as its products[103]. Corporate Governance and Management - The company held 3 shareholder meetings, 12 board meetings, and 8 supervisory meetings during the reporting period, passing a total of 72 resolutions[173]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 1,452.68 million[190]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 810.07 million[190]. - The company has not faced any penalties from securities regulatory authorities in the past three years[192]. - The company has not reported any objections raised by directors regarding company matters[195].

证券代码：688321 证券简称：微芯生物 公告编号：2023-028 深圳微芯生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 04 月 24 日(星期一) 下午 15:00-16:30 会议召开地点：深圳市南山区西丽街道曙光社区南山智谷产业园 B 栋 22 楼多功能厅，上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/）同步进行现场直播 会议召开方式：现场+上证路演中心视频直播和网络互动 投资者可于 2023 年 04 月 17 日(星期一) 至 04 月 21 日(星期 五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 ir@chipscreen.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 本次投资者说明会以现场互动+视频直播结合网络互动召开，公 司将针对 2022 年度经营成果及财务指标的具体情况与投资者进行互 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥119,751,736.11, representing a year-over-year increase of 28.44%[8] - The net profit attributable to shareholders for Q3 2022 was -¥22,922,857.19, with a year-to-date net profit of -¥42,211,182.77[8] - Total operating revenue for the first three quarters of 2022 reached CNY 335,672,990.64, an increase of 21.4% compared to CNY 276,545,965.86 in the same period of 2021[32] - The net loss attributable to shareholders of the parent company for Q3 2022 was CNY -42,211,182.77, compared to a net loss of CNY -24,254,905.09 in Q3 2021[39] - The company reported a total comprehensive loss of CNY -43,778,468.38 for Q3 2022, compared to a loss of CNY -24,254,905.09 in Q3 2021[39] - Basic and diluted earnings per share for Q3 2022 were both CNY -0.1037, compared to CNY -0.0591 in Q3 2021[39] Research and Development - Research and development expenses totaled ¥88,638,551.08 for Q3 2022, an increase of 42.21% compared to the same period last year[11] - R&D expenses accounted for 74.02% of operating revenue in Q3 2022, up by 7.17 percentage points year-over-year[11] - Research and development expenses increased to CNY 128,911,960.16 in Q3 2022, a rise of 40.9% from CNY 91,469,526.90 in Q3 2021[36] - The company continues to focus on independent R&D innovation, necessitating significant investment in R&D to advance ongoing projects[19] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥2,741,364,643.65, reflecting a 44.71% increase from the end of the previous year[11] - Total current assets increased to ¥1,127,300,392.95 from ¥638,821,140.58 year-over-year[28] - Total assets as of September 30, 2022, are ¥2,741,364,643.65, up from ¥1,894,406,023.56 at the end of 2021[31] - The company's fixed assets increased to ¥783,713,505.03 from ¥534,769,585.14 year-over-year[31] - Total liabilities increased to ¥340,987,100.09 from ¥293,839,051.54 year-over-year[31] - Total liabilities amounted to CNY 1,109,267,404.86, significantly higher than CNY 476,792,465.34 from the previous year[32] - Total equity attributable to shareholders of the parent company was CNY 1,568,761,648.34, up from CNY 1,417,613,558.22 in the previous year[32] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,752,038.31, down by 96.89% compared to the previous year[11] - Operating cash inflows totaled approximately ¥368.20 million, slightly up from ¥363.99 million year-over-year[42] - Operating cash outflows increased to ¥366.45 million from ¥307.65 million, resulting in a net cash flow from operating activities of ¥1.75 million, down from ¥56.34 million[42] - Investment cash inflows decreased significantly to ¥259.02 million from ¥706.77 million, while investment cash outflows rose to ¥884.03 million from ¥723.60 million, leading to a net cash flow from investing activities of -¥625.02 million[42] - Financing cash inflows surged to ¥1.11 billion from ¥172.93 million, with net cash flow from financing activities reaching ¥858.59 million, compared to -¥12.32 million previously[44] - Cash and cash equivalents at the end of the period stood at ¥549.93 million, up from ¥298.12 million[44] - The total cash increase for the period was ¥249.77 million, compared to an increase of ¥26.56 million in the prior year[44] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,781[20] - The largest shareholder, BGI Group, holds 42,919,572 shares, representing 10.45% of total shares[20] - The second largest shareholder, Shenzhen Haiyue Men Biotechnology Development Co., Ltd., holds 22,936,008 shares, representing 5.58%[20] - The company has not engaged in margin trading or securities lending activities among its top shareholders[23] Government Subsidies and Other Income - The company reported a total of ¥3,910,157.23 in government subsidies recognized in Q3 2022[13] - Cash received from sales of goods and services in the first three quarters of 2022 was CNY 351,391,756.24, an increase from CNY 314,128,886.49 in the same period of 2021[40] Financial Expenses - The company’s financial expenses included interest expenses of CNY 10,533,938.08 in Q3 2022, compared to CNY 3,095,043.70 in Q3 2021[36] Employee Compensation and Tax Payments - The company reported a significant increase in employee compensation payments, totaling ¥191.66 million, compared to ¥148.38 million last year[42] - Tax payments decreased slightly to ¥20.70 million from ¥22.04 million[42] Foreign Exchange and Other Gains - The company experienced a foreign exchange gain of ¥14.45 million, contrasting with a loss of ¥0.64 million in the previous period[44]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥215,921,254.53, representing a 17.79% increase compared to ¥183,307,290.44 in the same period last year[24]. - The net profit attributable to shareholders of the listed company was -¥19,288,325.58, compared to -¥7,152,330.88 in the same period last year, indicating a decline in profitability[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -22,583,405.81 RMB, a decrease compared to -14,797,302.70 RMB from the previous year[26]. - The net cash flow from operating activities increased by 29.29% to 22,877,669.34 RMB from 17,695,154.24 RMB in the same period last year[26]. - Total assets increased by 16.96% to 2,215,781,080.44 RMB compared to 1,894,406,023.56 RMB at the end of the previous year[26]. - Basic earnings per share decreased to -0.0474 RMB from -0.0174 RMB in the same period last year[26]. - The cost of goods sold increased by 57.99% to ¥13,675,867.61, primarily due to the growth in sales of the product Xidabonan[96]. - Research and development expenses rose by 31.31% to ¥76,002,719.79, driven by the ongoing progress of various research projects[96]. - The company reported a significant increase in short-term borrowings, which rose by 128.73% to ¥274,822,481.40[99]. Research and Development - The company continues to focus on research and development of innovative drugs targeting new mechanisms and pathways[14]. - Research and development expenses accounted for 60.52% of operating income, an increase of 4.96% compared to 55.56% in the previous year[26]. - The company has developed multiple innovative drug products, including Sidabenan (marketed) and others in various clinical trial phases[33]. - The overall progress of the company's R&D pipeline is advancing, with several products at different stages of clinical trials[33]. - The company is committed to advancing its research and development efforts to bring new therapies to market for unmet medical needs[42]. - The company has a pipeline of new molecular entities for oncology, metabolic diseases, autoimmune diseases, CNS diseases, and antiviral therapies, with candidates like CS32582 and CS271011 in preclinical research[46]. - The company integrates early research, clinical development, and GMP production in its innovative drug development model[49]. - The company has established a robust quality management system, achieving a 100% pass rate for product release during the first half of 2022[90]. - The company has received IND approval for multiple clinical trials, including a Phase II trial for the combination of chidamide and toripalimab for NSCLC, which began patient enrollment in December 2021[67]. Clinical Trials and Product Development - The company has developed a new drug, Chidamide, which is the first oral drug approved for treating peripheral T-cell lymphoma, with a unique mechanism as a selective HDAC inhibitor[42]. - The drug Xiglitazar is the first PPAR pan-agonist approved for treating type 2 diabetes, targeting insulin resistance, and has shown clear efficacy in blood glucose and lipid control[43]. - Xiglitazar is currently undergoing a Phase III clinical trial for combination therapy with metformin for type 2 diabetes patients inadequately controlled by metformin alone[43]. - The company has multiple ongoing clinical trials for Chidamide, including a Phase III trial for treating diffuse large B-cell lymphoma and a Phase II trial for non-small cell lung cancer[43]. - The company is advancing several registration clinical trials for Chidamide in international markets, including melanoma and non-small cell lung cancer[43]. - The company has reported significant progress in its clinical trials, with completed patient enrollment in several Phase III studies[43]. - The Phase III clinical trial for Sidabenan targeting diffuse large B-cell lymphoma (DLBCL) completed participant enrollment in July 2022, marking a global first for this indication[79]. - The Phase III clinical trial for Siglecatin combined with Metformin for type 2 diabetes also completed participant enrollment, with results analysis expected in Q1 2023[79]. - The company is actively pursuing clinical trials for new indications, including a Phase II trial for Xiglitazone in patients with non-alcoholic fatty liver disease[56]. Market Strategy and Sales - The company is focused on expanding its market presence through innovative drug development and strategic partnerships[42]. - The sales strategy includes a structured sales department to enhance market access and product strategy[49]. - The company is expanding its marketing service network by establishing offices in 30 cities, including Beijing, Shanghai, and Shenzhen, to meet the growing market demand[160]. - The company is enhancing internal controls and management levels to ensure normal operations, reduce management risks, and improve operational efficiency and profitability[160]. - The company is focused on expanding its marketing network and sales channels to enhance revenue generation[157]. Corporate Governance and Compliance - The report is unaudited, and the responsible persons have declared the accuracy and completeness of the financial report[7]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has established measures to avoid new industry competition commitments from major shareholders and management[143]. - The company has committed to strict compliance with securities laws regarding the trading of shares and convertible bonds for six months post-issuance[181]. - The company will disclose any failure to fulfill commitments, including specific circumstances and corrective measures, and will compensate investors for any losses incurred due to such failures[13]. Environmental and Social Responsibility - The company’s environmental protection measures include active carbon adsorption for waste gas treatment, complying with emission standards[119]. - The company’s waste gas emissions during the reporting period met environmental protection requirements, with specific VOCs emission limits set at 0.0288 tons per year[119]. - The company conducts monthly monitoring of volatile organic compounds and quarterly monitoring of hydrochloric acid and particulate matter[125]. - The company has established a green low-carbon production principle in its operations[130]. - The company conducts daily safety inspections and monthly safety checks to reduce carbon emissions[132]. Shareholder Commitments and Stock Management - The company has a commitment to not seek control over the company and has fulfilled this commitment[137]. - The company has implemented measures to compensate for the dilution of immediate returns[137]. - The company’s major shareholders have committed to adhere to legal regulations when reducing their holdings, ensuring compliance with the Company Law and Securities Law[144]. - The company will ensure that any share reductions after the lock-up period will be disclosed to maintain stable control over the issuer[144]. - The company has established measures to stabilize stock prices if the closing price falls below the audited net asset value per share for 20 consecutive trading days[150].